Empreses derivades

Tot i que no és una cosa que s'esperi en absolut dels investigadors ICREA, de vegades troben alguna cosa que promet de convertir-se en una potent tecnologia nova, però sembla impossible desenvolupar-la més sense una inversió significativa de temps i diners. En aquests casos, n'hi ha molts que opten per la creació d'una empresa especialitzada, que gràcies a l'aportació d'inversors, obtingui recursos per a convertir la idea en una realitat.

List of spin off companies


    Supported by the Universitat de Barcelona (UB) and ICREA.
    Entrepreneur: ICREA Research Professor Xavier Barril
    Born in October 2011. 

    view details


    Minoryx Therapeutics develops treatments for Inborn Errors of Metabolism, a group of rare diseases of genetic origin affecting 3,700 newborns every year in Europe. Such diseases are life threatening and highly debilitating, usually with neurological manifestations and affect most severely the pediatric population. The social and economic impact of these diseases cannot be overstated and, with 90% of cases lacking curative treatments, there is a high unmet medical need. Minoryx develops new drugs to improve both the quality of life and life expectancy of the patients.

    Minoryx has developed SEE-Tx (Site-directed Enzyme Enhancement Therapy), a technological platform that incorporates computational methods developed in the Barril’s lab at Barcelona University. SEE-Tx enables us to develop a new generation of drugs: the non-competitive pharmacological chaperones, which recover the functionality of mutated proteins, thus attacking the root of the disease. We have discovered non-competitive pharmacological chaperones in a range programs, which are at various stages of preclinical research.


    Supported by the Universitat Pompeu Fabra, Universitat Politècnica de Catalunya, Hospital Clínic de Barcelona and ICREA.
    Entrepreneur: ICREA Research Professor Miguel Á. González Ballester.
    Born in September 2019.

    view details


    MiWEndo Solutions develops MiWEndo, a novel medical device that applies microwave imaging technology to colonoscopy. MiWEndo aims to contribute to improving prevention and diagnosis of colorectal cancer, as well as serving as an exploratory tool to increase the scientific knowledge about this type of cancer. MiWEndo automatises the detection of  polyps and raises an alarm when one is detected. Furthermore, it augments the field of view to 360º and provides quantitative tissue classification, without any modification to current clinical procedures.

    Colon cancer is a highly prevalent and devastating disease. The current push for screening programs worldwide has led to an increase in colonoscopy procedures. Detection of polyps in these explorations highly relies on the experience of the clinical expert, and is therefore subject to subjectivity and fatigue. MiWEndo aims at providing a novel valuable tool to the clinician, thus contributing to reduce the number of missed polyps in colonoscopies.

    The global market for colonoscopy is approximately 1550M€, with a yearly increase of 5%. The main target markets for MiWEndo, at present, are Europe, USA and Japan. MiWEndo is a patented device, and it is safe, complementary to existing colonoscopes and low-cost. MiWEndo will lead to increased polyp detection rates and better decision support, by providing more information about the malignancy of the tissue. It will also reduce time and cost, in terms of faster explorations, less repeated colonoscopies, reduced patient preparation time and earlier detection and treatment of colorectal cancer.

    Further information:

    [1] González Ballester et al. (2017), European patent no. EP3195786A1.

    [2] Guardiola et al. (2018), Medical Physics, vol. 45(8), 3768-3782.

    [3] Guardiola et al. (2019), IEEE Transactions on Antennas and Propagation, vol. 67(8), 4968-4977.


    Jointly supported by the Vall d’Hebron Institut d’Oncologia (VHIO), the Vall d’Hebron Institut de Recerca (VHIR) and ICREA.
    Entrepreneur: ICREA Research Professor Joan Seoane.
    Born in April 2013. Liquidated in 2020.


    Supported by the Barcelona Supercomputing Center - Centro Nacional de Supercomputación (BSC-CNS), the Universitat de Barcelona (UB), the Institut de Recerca Bioèdica de Barcelona (IRB Barcelona) and ICREA.
    Entrepreneur: ICREA Research Professor Victor Guallar.
    Born in December 2015.

    view details


    Nostrum Biodiscovery is a biotechnological company focused on the computational biology sector and specifically; in the structure-based drug design area dedicated to early drug discovery and development based on rational design techniques.

    For 12 years, Dr. Modesto Orozco and Dr. Victor Guallar supported by top-tier public research institutions as Barcelona SuperComputing Center (BSC), Institute for Research in Biomedine (IRB Barcelona), ICREA and Universitat de Barcelona (UB) have been developing innovative in silico tools to reduce pharmaceutical and biotechnological R&D costs while improving the productivity and future profitability of the drug discovery process.

    Nostrum Biodiscovery technologies represents a unique breakthrough in this field since they will be bringing key features to pharmaceutical discovery users as the new approach to molecular simulation, target characterization, drug recognition and an integrated molecular dynamics into the drug value chain. 

  • OMNIA MOLECULAR (Inactive)

    Jointly supported by the Parc Científic de Barcelona (PCB), the Institut de Recerca Biomèdica (IRB Barcelona) and ICREA.
    Entrepreneur: ICREA Research Professor Lluís Ribas de Pouplana.
    Born in June 2005.